1. Home
  2. DCTH vs PGEN Comparison

DCTH vs PGEN Comparison

Compare DCTH & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DCTH
  • PGEN
  • Stock Information
  • Founded
  • DCTH 1988
  • PGEN 1998
  • Country
  • DCTH United States
  • PGEN United States
  • Employees
  • DCTH 76
  • PGEN N/A
  • Industry
  • DCTH Medical/Dental Instruments
  • PGEN Biotechnology: Pharmaceutical Preparations
  • Sector
  • DCTH Health Care
  • PGEN Health Care
  • Exchange
  • DCTH Nasdaq
  • PGEN Nasdaq
  • Market Cap
  • DCTH 426.3M
  • PGEN 475.2M
  • IPO Year
  • DCTH N/A
  • PGEN N/A
  • Fundamental
  • Price
  • DCTH $11.52
  • PGEN $1.85
  • Analyst Decision
  • DCTH Strong Buy
  • PGEN Strong Buy
  • Analyst Count
  • DCTH 4
  • PGEN 3
  • Target Price
  • DCTH $24.00
  • PGEN $6.00
  • AVG Volume (30 Days)
  • DCTH 873.0K
  • PGEN 2.2M
  • Earning Date
  • DCTH 08-04-2025
  • PGEN 08-13-2025
  • Dividend Yield
  • DCTH N/A
  • PGEN N/A
  • EPS Growth
  • DCTH N/A
  • PGEN N/A
  • EPS
  • DCTH N/A
  • PGEN N/A
  • Revenue
  • DCTH $53,850,000.00
  • PGEN $4,201,000.00
  • Revenue This Year
  • DCTH $155.42
  • PGEN $256.94
  • Revenue Next Year
  • DCTH $37.93
  • PGEN $759.81
  • P/E Ratio
  • DCTH N/A
  • PGEN N/A
  • Revenue Growth
  • DCTH 1068.87
  • PGEN N/A
  • 52 Week Low
  • DCTH $7.17
  • PGEN $0.65
  • 52 Week High
  • DCTH $18.23
  • PGEN $2.17
  • Technical
  • Relative Strength Index (RSI)
  • DCTH 32.83
  • PGEN 68.77
  • Support Level
  • DCTH $12.11
  • PGEN $1.56
  • Resistance Level
  • DCTH $14.15
  • PGEN $2.04
  • Average True Range (ATR)
  • DCTH 0.57
  • PGEN 0.11
  • MACD
  • DCTH -0.16
  • PGEN 0.04
  • Stochastic Oscillator
  • DCTH 9.67
  • PGEN 70.00

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

About PGEN Precigen Inc.

Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

Share on Social Networks: